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Angiotensin II blockade and low-protein diet produce additive
therapeutic effects in experimental glomerulonephritis
HARM PETERS, WAYNE A. BORDER, and NANCY A. NOBLE
Fibrosis Research Laboratory, University of Utah School of Medicine, Salt Lake City, Utah, USA
progression in humans with chronic renal failure may be slowedAngiotensin II blockade and low-protein diet produce additive
more effectively when Ang II blockade and low-protein diettherapeutic effects in experimental glomerulonephritis.
are combined. Since maximal pharmacological Ang II inhibi-Background. Transforming growth factor-b (TGF-b) over-
tion was used, it is likely that dietary protein restriction furtherexpression plays a key role in the accumulation of extracellular
reduces pathological TGF-b overexpression by mechanismsmatrix in acute and chronic renal diseases. Recent studies have
different from those of enalapril or losartan.suggested that the degree of reduction in pathological TGF-b
overexpression can be used as a therapeutic index to evaluate
the antifibrotic potential of pharmacological angiotensin II
(Ang II) blockade in renal disease. Using this target, we found
Despite major differences in the underlying disorder,that treatment with the angiotensin I-converting enzyme inhibi-
the histologic picture of chronic renal disease is uni-tor enalapril or the Ang II type 1 receptor antagonist losartan
reduced TGF-b overexpression more effectively at doses clearly formly characterized by progressive accumulation of ex-
higher than those required to control blood pressure. However, tracellular matrix proteins that obliterates renal function
both forms of Ang II blockade were only partially effective in and leads to organ failure [1]. A large body of work nownormalizing TGF-b expression. This study investigated whether
supports the hypothesis that overexpression of the cyto-a greater antifibrotic, TGF-b–reducing benefit can be achieved
kine transforming growth factor-b (TGF-b) plays a keywhen Ang II blockade is combined with dietary protein re-
striction. role in the progressive matrix accumulation and tissue
Methods. Mesangioproliferative glomerulonephritis was in- fibrosis in all organs in which fibrosis occurs, including
duced in male Sprague-Dawley rats on a normal-protein diet. the kidney [1, 2]. A number of factors known to be injuri-Treatment with a low-protein diet and/or maximally effective
ous to the kidney at the cellular or molecular level havedoses of enalapril or losartan was started one day after disease
now been shown to increase TGF-b expression [re-induction. On the fifth day, 24-hour urine protein excretion
was measured. On the sixth day, cortical kidney tissue was viewed in 2]. These include high glucose levels, hypoxia,
taken for periodic acid-Schiff staining. Isolated glomeruli were immune complexes, advanced glucosylated end prod-
used for mRNA extraction or were placed in culture for deter-
ucts, mesangial cell stretch, protein trafficking, platelet-mination of production of TGF-b1, the matrix protein fibro-
derived growth factor, basic fibroblast growth factor, andnectin, and the protease inhibitor plasmin activator inhibitor
type 1 (PAI-1) by enzyme-linked immunosorbent assay. TGF-b itself. TGF-b overproduction in turn mediates
Results. Compared with untreated nephritic animals on a local expansion of extracellular matrix through increased
normal-protein diet, a single treatment with enalapril, losartan, matrix production, decreased matrix degradation, and
or low-protein diet significantly reduced glomerular TGF-b
increased local expression of matrix-binding receptors.production, albeit to a similar degree of approximately 45%.
Blocking TGF-b overexpression with neutralizing anti-A moderate, but significant further reduction in pathological
TGF-b expression of a total of 65% for enalapril and 60% for bodies has now been shown to reduce matrix expansion
losartan was achieved when these drugs were combined with in a number of models of fibrotic diseases in tissues,
low-protein feeding. This reduction in TGF-b overexpression including kidney, artery, joint, lung, liver, and the centralparalleled decreased proteinuria, glomerular matrix accumula-
nervous system [1, 3, 4].tion, and overproduction of fibronectin and PAI-1.
Blockade of angiotensin II (Ang II) with angiotensin-1–Conclusions. Ang II blockade and low-protein diet have
additive effects on disease reduction, suggesting that disease converting enzyme (ACE) inhibitors or the newly avail-
able class of Ang II type 1 (AT1) receptor antagonists
significantly limits renal matrix expansion in numerousKey words: TGF-b, angiotensin, low-protein diet, kidney, extracellular
matrix, progressive renal disease. experimental acute and chronic renal diseases [2, 5]. In
patients with chronic renal failure, ACE inhibition re-Received for publication November 4, 1998
duces proteinuria, slows the fall in the glomerular filtra-and in revised form October 18, 1999
Accepted for publication November 1, 1999 tion rate, and delays the need for dialysis or transplanta-
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molecule of the renin-angiotensin system (RAS) and has that additional pathways must be targeted. Supporting
this conclusion are recent data from Fern et al, wholong been known as a potent vasoconstrictor. Besides
increasing hypertensive damage to the kidney, several showed that fibrosis is reduced by only about 50% in
mice with obstructive nephropathy in which the angio-recent studies have shown that Ang II also has important
blood pressure-independent actions leading to matrix ac- tensinogen gene has been disrupted [14].
A prime candidate to further reduce renal TGF-b over-cumulation [2]. Direct pressure-independent induction of
TGF-b overexpression has emerged as a central feature expression and tissue fibrosis in the presence of Ang II
blockade is restriction of dietary protein intake. Theof this work [2, 6, 7]. In cultured mesangial cells, the
induction of matrix proteins such as collagens, fibronec- protective effects of lowering protein intake were first
demonstrated in a model of nephrotoxic serum nephritistin, and proteoglycans by Ang II is preceded by induction
of TGF-b expression and can be blocked by a TGF-b– in the late 1930s [15]. Subsequently, low protein intake
has been shown to improve disease course and limitneutralizing antibody [8]. In further studies, we have
shown that the sustained effect of Ang II on synthesis matrix expansion in virtually all renal diseases [16]. In
contrast, increased protein intake has been shown toof the key protease inhibitor, plasmin activator inhibitor
type 1 (PAI-1) is also mediated via induction of TGF-b, worsen experimental diseases [17]. Despite continued
controversy and questions about the mechanism of ac-while the initial short-term effect appeared to be induced
by Ang II directly [9]. Comparable work on pressure- tion, as recently reviewed by Heidland, Sebekova, and
Ling [18], several clinical trials have suggested that pro-independent Ang II effects has been done using proximal
tubular cells [7, 10]. In addition, Ang II induces several tein restriction effectively slows the progressive loss of
renal function in patients with chronic renal failure. Stud-chemokines that lead to infiltration of monocytes/macro-
phages [7, 11], effects that may be mediated by TGF-b. ies have shown that low-protein feeding significantly re-
duces TGF-b overexpression following the induction ofExciting preliminary data further indicate that Ang II
enhances TGF-b’s fibrogenic activities by up-regulation ATS GN [19]. These results were later confirmed by
others in models of puromycin- and adriamycin-inducedof TGF-b receptor expression, thereby increasing the
actions of exogenous TGF-b to increase matrix protein GN [20, 21], and are consistent with the concept that
antifibrotic effects are mediated through a reduction insynthesis (abstracts; Kanai et al, J Am Soc Nephrol
8:518A,1997; J Am Soc Nephrol 9:498A,1998). In experi- TGF-b overexpression.
In the present study, we tested the hypothesis that themental kidney diseases, in turn, the decrease in renal
matrix expansion by Ang II blockade is paralleled by a antifibrotic effect of maximally effective doses of Ang II-
blocking drugs can be enhanced by simultaneously feed-reduction in TGF-b overexpression, suggesting that its
therapeutic effects are mediated through reduction of ing a low-protein diet. Again, using ATS GN in the rat,
we show that treatment with enalapril or losartan or low-TGF-b [2]. Human data are beginning to emerge show-
ing that ACE inhibition lowers TGF-b levels in chronic protein diet alone reduces glomerular TGF-b production
approximately 45%. A significant further reduction inhuman kidney diseases [12].
Our laboratory has recently been involved in testing glomerular TGF-b overexpression and all disease mea-
sures is achieved when enalapril or losartan treatment isthe hypothesis that the efficacy of current or promising
antifibrotic drugs can be determined by their potential combined with dietary protein restriction. A major differ-
ence between these and earlier studies with a low-proteinto reduce TGF-b overexpression. We have further asked
whether the addition of a second therapy to one drug diet is the attempt to quantitate therapeutic efficacy.
given at doses that maximize TGF-b reduction alone
can enhance efficacy [13]. Using this approach, we have
METHODS
recently shown that treatment with either the ACE in-
Materialshibitor enalapril or the AT1 receptor blocker losartan
produces a dose-dependent reduction in glomerular If not otherwise indicated, materials, chemicals, or
culture media were purchased from Sigma Chemical Co.TGF-b overexpression and matrix accumulation in the
antithymocyte serum (ATS) model of mesangioprolifer- (St. Louis, MO, USA).
ative glomerulonephritis (GN) [13]. Although maximal
Experimental designdisease reduction was seen at doses that were clearly
higher than those known to control blood pressure, In rats following the induction of acute GN, we tested
the hypothesis that the antifibrotic effect of Ang II-block-TGF-b overproduction and other measures of disease
could not be reduced by more than 50%, even with ing drugs can be enhanced by additional low-protein
restriction. GN was induced in rats fed a normal-proteinextremely high doses. Furthermore, no additive effects
were seen when both forms of Ang II blockade were diet. Treatment was started 24 hours after antibody injec-
tion when mesangial cell lysis is complete and the fibroticgiven. The data strongly suggest that pharmacological
blockade of Ang II alone will not halt renal fibrosis and response starts. Single therapy with enalapril, losartan,
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or a low-protein diet was compared side by side with that the doses used in these experiments maximally re-
duced glomerular TGF-b overexpression and matrix ac-combined treatment with low-protein feeding and enala-
pril or losartan. Renal tissues were harvested six days cumulation in this model [13]. Sixty percent of the first
daily dose of enalapril or losartan (based on 40 mL drink-after disease induction, at a time point when previous
time-course studies had shown that the fibrotic response ing volume per day) was administered by gavage 24 hours
after OX-7 injection. Water and drug intake was moni-was maximal.
A reduction in TGF-b overexpression served as the tored daily. Diets included a normal-protein diet (22%
casein) and a low-protein diet (6% casein, Teklad dietprinciple measure of antifibrotic action. A histologic ma-
trix score was used to determine whether the changes 86551; Teklad Premier Laboratory Diets). The diets
were identical in fat and mineral content and were madein TGF-b expression reflect the actual renal matrix accu-
mulation. Measurements of the matrix component fi- isocaloric (14.6 J/g) by the addition of sucrose.
One day after the induction of GN, treatment wasbronectin and the protease inhibitor PAI-1 were used
as sensitive markers of TGF-b’s action. TGF-b1, fibro- started. Rats (8 per group) were assigned to the following
therapies: (1) controls on normal protein, (2) GN onnectin, and PAI-1 expression were measured at the pro-
tein level in the supernatant of cultured glomeruli and normal protein, (3) GN on low protein, (4) GN on nor-
mal protein plus enalapril, (5) GN on normal proteinat the mRNA level by Northern blotting.
plus losartan, (6) GN on low protein plus enalapril, and
Animals (7) GN on low protein plus losartan.
Male Sprague-Dawley (SD) rats (200 to 270 g) ob-
Measurement of blood pressure and proteinuriatained from Sasco (Omaha, NE, USA) were fed a normal
protein diet (22% protein, Teklad no. 86550; Teklad Systolic blood pressure was measured in conscious
animals five days after disease induction by the tail-cuffPremier Laboratory Diets, Madison, WI, USA) for at
least three days before the start of the experiment to method [13]. During the following 24 hours, rats were
individually housed in metabolic cages for urine collection.allow equilibration.
Proteinuria was measured using the Bradford method and
Disease induction is expressed as mg protein/24 h.
Glomerulonephritis was induced by tail-vein injection
Sacrificeof the monoclonal anti-Thy 1.1 antibody OX-7 (1.5 mg/kg)
under light methoxyflurane anesthesia. In the kidney, Animals were anesthetized with ether six days after
the induction of GN. Following a midline abdominalthe monoclonal antibody binds to a Thy 1-like epitope
on the surface of mesangial cells and causes complement- incision, 5 to 10 mL of blood were drawn from the lower
abdominal aorta, and the kidneys were subsequently per-dependent cell lysis. Control animals were injected with
equal volumes of phosphate buffered saline (PBS). Body fused with 30 mL ice-cold PBS. For histologic examina-
tion, cortical tissue was fixed in 10% neutral-bufferedweight, food, and water intake were monitored individu-
ally at the beginning and end of each experiment. formalin. Glomeruli from individual rats were isolated
by a graded sieving technique (150, 125, 106, and 75 mm
OX-7 production mesh metal sieves) as described previously [13].
OX-7 was produced as previously described [13]. The
Light microscopyhybridoma cells were obtained from American Type
Culture Collection (Rockville, MD, USA). Briefly, the All microscopic examinations were performed in a
blinded fashion. Three micrometer sections of paraffin-hybridoma was grown in ascitic fluid of adult female
BALB/c mice (Charles River, Wilmington, MA, USA) embedded tissue were stained with periodic acid-Schiff
(PAS). Glomerular matrix expansion was evaluated asand was purified using a Protein G column (Pierce, Rock-
ford, IL, USA). The eluant was dialyzed extensively previously described [13]. Briefly, in 30 glomeruli from
each rat, the percentage of matrix occupying each glo-against PBS (pH 7.4). The antibody concentration was
adjusted to 1 mg/mL based on the absorbance at 280 nm merulus was rated as follows: 0 5 0%, 1 5 25%, 2 5
50%, 3 5 75%, and 4 5 100%.and was stored at 2708C until use.
Treatments Production of TGF-b1, fibronectin, and PAI-1 by
glomeruli in cultureAngiotensin II blockade was performed as previously
described [13]. The ACE inhibitor enalapril (Enal, 100 Glomeruli from individual rats were resuspended in
Dulbecco’s modified Eagle’s medium supplemented withmg/L) and the AT1 antagonist losartan (Los, 500 mg/L)
were given in the drinking water. Losartan was kindly 0.1 U/mL insulin, 100 U/mL penicillin, 100 mg/mL strep-
tomycin, and 25 mmol/L HEPES buffer. After 72 hoursprovided by DuPont Merck Pharmaceuticals Co. (Wil-
mington, DE, USA). In a previous study, we have shown of incubation at 378C/5% CO2, the supernatant was har-
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vested and stored at 2708C until analysis of glomerular
TGF-b1, fibronectin, and PAI-1 production. TGF-b1
production of cultured glomeruli was measured after acid
activation using a commercially available enzyme-linked
immunosorbent assay (ELISA) kit (Quantikinee; R&D
Systems, Minneapolis, MN, USA) according to the man-
ufacturer’s instructions. Fibronectin and PAI-1 synthesis
were measured with modified inhibitory ELISAs ac-
cording to published methods [22]. Three samples from
each rat were analyzed.
RNA preparation and Northern hybridization for
TGF-b1, fibronectin, PAI-1, and GAPDH
Total RNA was extracted immediately from freshly iso-
lated glomeruli by a guanidinium isothiocyanate method
using Trizolt Reagent according to the manufacturer’s
Fig. 1. Twenty-four–hour urinary protein excretion measured in sam-instructions. Isolated glomeruli from two to four rats
ples collected from days 5 and 6 of mesangioproliferative glomerulone-
were pooled for subsequent RNA extraction. For North- phritis (GN). The animals were fed either a normal-protein (NP, 22%
casein) or a low-protein diet (LP, 6% casein). Enalapril (Enal, 100 mg/L)ern analysis, RNA was denatured and fractionated by
or losartan (Los, 500 mg/L) was given in the drinking water (*P , 0.01electrophoresis through a 1.8% agarose gel (30 mg/lane) vs. NP; #P , 0.05 vs. LP, NP 1 Enal, or NP 1 Los).
and transferred to a Hybond nylon membrane (Amers-
ham Corp., Little Chalfont, UK). Nucleic acids were
immobilized by ultraviolet irradiation. Membranes were
animals. Treatment with Ang II blockade or low-proteinprehybridized with 50% formamide, 10% Denhardt’s
diet did not significantly change systolic blood pressure.solution, 0.1% sodium dodecyl sulfate (SDS), 5 3 stan-
dard saline citrate (SSC), and 200 mg/mL denatured
Effect of disease inductionsalmon sperm DNA and hybridized with DNA probes
As shown in Figure 1, control animals excreted 13 6labeled with 32P-dCTP by random oligonucleotide prim-
2 mg of protein in the 24 hours before sacrifice. In theing (Boehringer Mannheim Biochemicals, Indianapolis,
untreated nephritic rats, proteinuria increased to 41 6IN, USA). The blots were washed in 2 3 SSC, 0.1%
5 mg/24 h. Injection of OX-7 resulted in an 8.6-foldSDS at room temperature for 15 minutes, and 0.1 3
increase in TGF-b1 production, a 16.3-fold increase inSSC, 0.1% SDS at 558C for 30 minutes. DNA probes used
fibronectin production, and a 15.5-fold increase in glo-were (1) rat glyceraldehyde-3-phosphate dehydrogenase
merular PAI-1 production by glomeruli isolated at day(GAPDH) cDNA (a gift form Drs. P. Kondaiah and
6 (Fig. 2). At the mRNA level, corrected for GAPDHM.B. Sporn) [23], (2) TGF-b1 cDNA (kindly provided
expression, TGF-b1 expression increased 3.6-fold, fi-from Dr. D.L. Moses) [24], (3) fibronectin-EDA cDNA
bronectin expression 18.9-fold, and PAI-1 expression by(a generous gift from Dr. R.O. Hynes) [25], and (4)
24.7-fold, respectively (Fig. 3). The glomerular matrixPAI-1 cDNA (kindly provided by Dr. T.D. Gelehrter)
score in the PBS-injected controls was 1.12 6 0.04 and[26]. Three blots per probe were performed.
increased to 2.56 6 0.04 after OX-7 injection (Fig. 2).
Statistical analysis
Effect of single treatment with enalapril, losartan orData are expressed as means 6 SEM. Statistical analy-
low proteinsis between the groups was performed by analysis of
variance (ANOVA) and subsequent t-testing with Bonf- Compared with the disease control animals, treatment
erroni correction for multiple comparison. A P value , of nephritic rats with either a low-protein diet, enalapril,
0.05 was considered as significant. or losartan resulted in a statistically significant, but very
similar, reduction in all measures of disease. Proteinuria
in the 24 hours before sacrifice was equally decreased
RESULTS
in all three groups with single treatment. From untreated
Basic data disease group values of 41 6 5 mg, the mean was 19 6
5 mg protein per 24 hours in low-protein group, 20 6 3Body weight, food consumption, and drinking volume
were not significantly different between the groups. Sys- mg in the enalapril, and 17 6 3 mg in the losartan groups,
respectively (Fig. 1). Compared with the disease controltolic blood pressure was 112 6 9 mm Hg in normal
control rats and 108 6 11 mm Hg in untreated nephritic animals (2.56 6 0.04), glomerular matrix score decreased
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Fig. 2. Glomerular matrix accumulation (A), glomerular production of transforming growth factor-b1 (TGF-b1; B), fibronectin (C), and platelet
activator inhibitor type 1 (PAI-1; D) six days after the induction of mesangioproliferative glomerulonephritis (GN). The animals were fed either
a normal-protein (NP, 22% casein) or a low-protein diet (LP, 6% casein). Enalapril (Enal, 100 mg/L) or losartan (Los, 500 mg/L) was given in
the drinking water (*P , 0.01 vs. NP; #P , 0.05 vs. LP, NP 1 Enal, or NP 1 Los).
to 2.12 6 0.04 in low-protein–treated, to 2.08 6 0.08 in restriction by 46%, with enalapril treatment by 43%, and
with losartan treatment by 36%, while glomerular PAI-1the enalapril-treated, and to 2.08 6 0.12 in losartan-
treated and nephritic animals (Fig. 2). The changes in production decreased by 41, 33, and 36%, respectively
(Fig. 2). These data indicate that similar reductions inTGF-b1 production paralleled glomerular matrix accu-
mulation and were also similarly reduced in all three TGF-b1 expression with different drugs lead to similar
reductions in matrix protein and PAI-1 production. Nonegroups, indicating that glomerular TGF-b production is
a valid indicator of histologic glomerular matrix expan- of these parameters were significantly different between
the nephritic animals treated with low-protein diet, ena-sion. TGF-b1 production was reduced with dietary pro-
tein restriction by 49%, with enalapril by 42%, and with lapril, or losartan alone.
Northern blotting was performed to analyze whetherlosartan treatment by 42% (Fig. 2). The differences be-
tween these groups were not significantly different. the reduction of TGF-b1, fibronectin, and PAI-1 achieved
by enalapril, losartan, or low-protein diet at the proteinChanges in TGF-b1 production were also closely par-
alleled by changes in glomerular fibronectin and PAI-1 level were related to decreased mRNA expression of
these components. As shown in Figure 3, the expressionproduction, both sensitive indicators of TGF-b’s action.
Fibronectin production was reduced with dietary protein of the glomerular TGF-b1, fibronectin, and PAI-1 mRNA,
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Fig. 3. Relative glomerular mRNA expression of TGF-b1 (A), fibronectin (B), and PAI-1 (C) six days after the induction of mesangioproliferative
glomerulonephritis (GN). (D) A representative Northern blot (one representative out of three). The animals were fed either a normal-protein
(NP, 22% casein) or a low-protein diet (LP, 6% casein). Enalapril (Ena, 100 mg/L) or losartan (Los, 500 mg/L) was given in the drinking water
(*P , 0.05 vs. NP). Molecular size markers are shown on the right.
corrected for GAPDH, showed the same pattern as their at least in part through reduced expression of TGF-b,
production by nephritic glomeruli, although the relative fibronectin, and PAI-1 mRNA.
reduction was less pronounced than the results in the
Effect of combined treatment with angiotensin IIprotein production (Fig. 2). Compared with the mRNA
blockade and low-protein dietexpression seen in the disease control animals, TGF-b
expression was reduced 23% with dietary protein restric- As shown in the right-hand bars of Figure 1, cotreat-
ment with enalapril or losartan and dietary protein re-tion, 24% with enalapril, and 22% with losartan (P ,
0.05). Glomerular mRNA expression of fibronectin was striction resulted in a significantly greater reduction in
urinary protein excretion than single therapy (P , 0.05).reduced by 38, 32, and 47%, while glomerular PAI-1
mRNA expression decreased by 31, 25, and 39% with Similarly, compared with the animals treated with enala-
pril only (2.08 6 0.08), adding low protein reduced thelow protein, enalapril, and losartan, respectively, (P ,
0.05). The differences between the three groups were not matrix score to 1.76 6 0.08. In the losartan-treated ani-
mals, additional dietary protein restriction reduced thesignificant. Thus, the data suggest that these therapies act
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matrix score from 2.08 6 0.12 to 1.64 6 0.04 (Fig. 2). dietary protein restriction significantly reduced patho-
logical TGF-b overexpression following induction ofCotreatment also resulted in a significantly greater re-
duction in glomerular TGF-b (Fig. 2). Compared with GN, but none of the three therapies were superior. How-
ever, a moderate but significant additional reduction inenalapril alone (42%), an addition of low-protein diet
reduced TGF-b overexpression by 65%. The addition TGF-b overexpression and most other measures of dis-
ease was achieved when Ang II blockade and low proteinof low-protein diet to losartan therapy reduced TGF-b
overexpression from 42 to 60%. intake were combined.
The results presented here for the low-protein dietConsistent with data on single therapy, the changes
in glomerular fibronectin and PAI-1 production closely group differ somewhat from our earlier data using the
ATS model of GN [19]. While we cannot be sure of thefollowed the changes seen in TGF-b production (Fig.
2), indicating comparable reductions in TGF-b’s action. reasons for an apparently more pronounced effect of
protein restriction seen earlier, a number of possibilitiesCompared with disease control animals, a combination
of low-protein diet and enalapril reduced glomerular exist. Earlier studies did not aim to quantitate therapeutic
effect but merely to show a significant effect. We nowfibronectin production by a total of 72% and glomerular
PAI-1 synthesis by a total of 61%. Similarly, losartan use highly sensitive ELISA techniques to quantitate in
vitro glomerular production of proteins of interest. Pilotplus a low-protein diet resulted in a total reduction of
63% in fibronectin and 59% in PAI-1 production. experiments have shown that TGF-b, PAI-1, and fibro-
nectin production are linear for both normal and diseasedGlomerular mRNA analysis of TGF-b1, fibronectin,
and PAI-1 expression corrected for GAPDH showed glomeruli for 72 hours, after which it falls (unpublished
data). ELISA data are also obtained from individual rats,the same pattern as the production of corresponding
proteins by nephritic glomeruli, although they did not whereas Northern blotting currently requires pooling of
RNA from three to four rats. The largest differencereach statistical significance. Compared with the mRNA
expression found in untreated nephritic rats, therapy between this and the earlier study of low protein is in
the data for PAS-stained tissue. However, quantitationwith enalapril and low-protein diet reduced glomerular
of PAS staining is by far the most variable of the mea-TGF-b1 mRNA by a total of 30%, fibronectin mRNA
sures presented both because of variability in tissue sec-by 58%, and PAI-1 mRNA by 45%. In the losartan-
tioning, staining intensity, and variability between scores.treated animals fed a low-protein diet, total reductions
Because we have obtained very similar data in otherin TGF-b1, fibronectin, and PAI-1 mRNA expression
studies using Ang II blockade [13] and low protein [27],were 27, 73, and 56%, receptively. None of these parame-
we believe the data presented here more precisely repre-ters were significantly different between the rats treated
sent the true efficacy of these therapies in this modelwith enalapril and a low-protein diet and those treated
than earlier published work.with losartan and a low-protein diet.
An earlier study reported an additive therapeutic ef-
fect of captopril and low protein in unilaterally nephrec-
DISCUSSION tomized rats [28]. The present report confirms and ex-
The present study demonstrates that the combination pands this earlier report in a number of important ways.
of Ang II blockade and a low-protein diet reduces glo- First, this study goes to the molecular level by showing
merular TGF-b overexpression and matrix accumulation that the decrease in matrix accumulation is likely to
more effectively than treatment with low-protein diet, result from both reduced matrix synthesis, as exemplified
enalapril, or losartan alone. The data further validate by data on fibronectin, and less inhibition of matrix deg-
our approach of evaluating, contrasting, and maximizing radation, as shown by the PAI-1 data. Second, the use
the antifibrotic actions of currently established and of AT1 receptor antagonist losartan shows that additive
promising new therapies for progressive fibrotic renal effects shown with ACE inhibition and low-protein diet
diseases by examining their potential to reduce patholog- also apply to receptor antagonists. Third, the doses of
ical TGF-b expression [13]. The changes in histologic enalapril or losartan used here are those that have re-
matrix accumulation closely followed the reductions in cently been shown to produce maximal therapeutic ef-
TGF-b overexpression, as did the in vivo indicators of fects in this model [13]. The use of maximally effective
TGF-b’s action: fibronectin and PAI-1. Because TGF-b doses of enalapril and losartan is important. If drugs
production by glomeruli in vitro is many-fold higher in that have the same mechanism of action are given at
nephritic animals, its use as a measure of disease severity submaximal doses, additive effects can result simply from
provides a much larger window to contrast effects of a dosing effect. However, if maximal doses are used and
single or combined therapeutic interventions than con- additivity is found, different mechanisms of action of the
ventional variables such as histologic score or protein- drugs are suggested. Thus, the finding that dual therapy
uria. As expected from previous studies [13, 19], we results in further reductions of TGF-b overproduction
and a further reduction in TGF-b’s fibrogenic actionsfound that single therapy with Ang II-blocking drugs or
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strongly suggests that these therapies act, to some extent, intake. The addition of low protein to Ang II blockade
does significantly boost efficacy, but the effect is smallon different stimuli to TGF-b overexpression.
Consistent with our previous report, the present study relative to differences between no treatment and single
therapy. Thus, in the complex situation that exists indemonstrates that treament with maximally effective
doses of enalapril or losartan reduces glomerular TGF-b human clinical trails, such a small effect may be difficult
to detect. Supporting this concept is a human study byoverexpression and matrix accumulation to a similar ex-
tent [13]. At first glance, this may favor the notion that Ihle et al showing that the therapeutic effect of low-
protein diet can be easily demonstrated in a small num-their main therapeutic action is mediated through inhibi-
tion of Ang II as the principal effector molecule of the ber of patients when ACE inhibitors are not used [37].
The ATS model of GN is a well-characterized modelRAS. However, there is increasing evidence that addi-
tional effects of ACE inhibition such as bradykinin/nitric of acute tissue injury followed by fibrotic repair. One
may argue that chronic progressive disease differs fromoxide accumulation or additional effects of receptor an-
tagonism due to accumulation of Ang II breakdown acute reversible disease and that renal disease in rats dif-
fers from that seen in humans. A strong counter argumentproducts may be operating [13, 29, 30]. High circulating
levels of Ang II resulting from receptor antagonism may is that the similarities are far greater than the differences.
TGF-b overproduction has been shown in essentially allactivate AT2 receptors or produce increases in angioten-
sin breakdown products that may have important biolog- fibrotic diseases in which it has been investigated [2, 6].
Furthermore, the degree of TGF-b overexpression isical actions [30, 31]. Both activation of AT2 receptors and
increased levels of angiotensin fragments have recently generally correlated with the rate of accumulation of the
extracellular matrix. Rapidly progressing disease such asbeen linked to increases in the bradykinin/nitric oxide
pathway [13]. HIV nephropathy or anti-glomerular basement mem-
brane disease show marked overexpression of TGF-b,Compared with Ang II blockade, the mechanisms un-
derlying the antifibrotic action of low-protein diet are while slowly progressing diabetic nephropathy shows
more slowly increasing TGF-b overexpression [38–40].far less understood. Studies by Rosenberg et al have
shown that low-protein feeding markedly reduces renal Therefore, we argue that the present study may be rele-
expression of renin and angiotensinogen, suggesting that vant for treatment of patients with chronic renal failure,
a low-protein diet, similar to Ang II blockade, acts through and suggest that use of a combination of Ang II blockade
a reduction of renal RAS [5]. However, the finding here and protein restriction in chronic human renal diseases
that dietary protein restriction further reduces pathologi- might be beneficial.
cal TGF-b overexpression in the presence of maximal In conclusion, the present study shows that double
pharmacological Ang II inhibition strongly implies that therapy with Ang II blockers and a low-protein diet sig-
a low-protein diet has therapeutic actions separate from nificantly enhances therapeutic efficacy in renal fibrosis.
those of enalapril or losartan. It is conceivable that these The results suggest that low protein acts by pathways in
actions involve RAS. For example, a low-protein diet addition to blocking Ang II and supports the concept
may reduce the very high plasma renin levels caused by that the rate of progression can be retarded more effi-
Ang II blockade. Low protein may also act on pathways ciently when Ang II blockade is combined with dietary
independent of RAS. We have recently reported that a protein restriction in patients with chronic renal failure.
lower intake of the semiessential amino acid l-arginine
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